Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR1 mutation	Breast Cancer	FGFR1 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
FGFR1 mutation	Non Small Cell Lung Cancer	FGFR1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR1 mutation	Non Small Cell Lung Cancer	FGFR1 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR1 mutation	Urothelial Cancer	FGFR1 mutation	Urothelial Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 mutation	Melanoma	FGFR1 mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
FGFR1 mutation	Melanoma	FGFR1 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
FGFR1 mutation	Melanoma	FGFR1 mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
FGFR1 mutation	Urothelial Cancer	FGFR1 mutation	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR1 mutation	Glioma	FGFR1 mutation	Glioma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 mutation	Esophageal Cancer	FGFR1 mutation	Esophageal Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D
FGFR1 mutation	Estrogen Receptor Positive Breast Cancer	FGFR1 mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Resistant: D – Preclinical fulvestrant Resistant : D	fulvestrant Resistant: D – Preclinical fulvestrant Resistant : D
FGFR1 mutation	Estrogen Receptor Positive Breast Cancer	FGFR1 mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: D – Preclinical palbociclib Resistant : D	palbociclib Resistant: D – Preclinical palbociclib Resistant : D
FGFR1 mutation	Gastric Cancer	FGFR1 mutation	Gastric Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D
FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D